Bio-Rad Laboratories Inc. (NYSE: BIO and BIOb) today announced the launch of an assay website that allows droplet digital PCR (ddPCR™) users to locate existing assays or design new ones for mutation ...

Biodesix, Inc., a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which Biodesix will conduct the development, clinical validation, and ...

Bio-Rad Laboratories BIO recently announced the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include the company's QX Continuum ddPCR system, along with ...

This research collaboration aims to generate clinical evidence across a range of cancer types to support the implementation of Bio-Rad’s Droplet Digital™ PCR (ddPCR™) technology for tumor-informed ...

Earnings Call Insights: Bio-Rad Laboratories, Inc. (BIO) Q2 2025 Norman Schwartz, Chairman & CEO, indicated Bio-Rad delivered solid execution in Q2 2025, with both revenue and operating margin ...

Adeno-associated viruses (AAV) are powerful instruments in gene therapy. AAV particles comprise a protein capsid that along with the desired genome, containing both is considered a full capsid.

A CRISPR system detects rare cancer mutations in blood with single-nucleotide precision, outperforming ddPCR through engineered RNA guides and isothermal amplification. (Nanowerk Spotlight) Hidden ...

Dpcr Market To Surpass US$14.34 Billion By 2031, Propelled By Escalating Demand For High‐Precision Genetic Analysis - New Industry Research By The Insight Partners.. Growing demand for sensitive and ...